Navigation Links
Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty

LAUSANNE, Switzerland, January 13, 2014 /PRNewswire/ --

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that it has completed the recruitment of patients for its Phase III clinical study in Central Precocious Puberty (CPP) with triptorelin 22.5 mg.

Debiopharm is investigating the efficacy and safety of the gonadotropin releasing hormone (GnRH) agonist analog triptorelin pamoate 6-month formulation in the treatment of children suffering from central (GnRH-dependent) precocious puberty (CPP). CPP is defined by pubertal development occurring before the age of 8 years in girls and 9 years in boys, which is not secondary to exposure to sex steroids of adrenal or gonadal origin (peripheral precocious puberty). This 6-month formulation offers an excellent treatment option in a pediatric indication due to less frequent injections. No GnRH agonist 6-month formulation is currently approved for treatment of precocious puberty. The study is an international, multicenter, non-controlled phase III study on the efficacy, pharmacokinetics and safety of two consecutive intramuscular injections of the triptorelin pamoate 22.5 mg 6-month formulation over 12 months. The protocol has gone through the US Food and Drug Administration (FDA) Special Protocol Assessment procedure. The recruitment has been completed and the results are expected in Q4 2014.

"We are very happy to have completed the recruitment in this study," said Eija Lundström, Medical Director responsible for this project at Debiopharm International. "We are looking forward to the results at the end of this year as we believe that the 6-month formulation will simplify the treatment of CPP and make it more tolerable for this young population of patients."

About CPP

The onset of precocious pubertal development is the result of a premature activation of the pulsatile secretion of hypothalamic GnRH leading to an increase in pituitary LH (luteinising hormone) and to a lesser degree FSH (follicle stimulating hormone) secretion. It is characterized by early pubertal changes as well as acceleration of growth velocity and bone maturation. The condition is estimated to occur in about 1 out of every 5'000 to 10'000 children and is more common in girls than in boys.

About GnRH agonists in CPP

GnRH agonists have been the standard of care in the management of CPP for almost 30 years, including the triptorelin 1- and 3-month formulations manufactured by Debiopharm or its licensees. Chronic administration of triptorelin causes down- and dys-regulation of the pituitary GnRH receptors and suppresses LH and FSH secretion and ultimately the release of sex-hormones. The goal of the therapy is to stop the premature bone maturation and to avoid a compromised adult height and the social and psychological difficulties associated with premature sexual development. The treatment is generally well tolerated with acceptable adverse effects of minor severity.

About triptorelin

Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). Debiopharm signed a licensing agreement for triptorelin with Tulane University in the US. Triptorelin was discovered by Prof. Andrew Schally who received the Nobel Prize in 1977. Debiopharm has since developed three slow-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month-formulations have been registered in most countries and are currently available under the names of Trelstar® in North America, Decapeptyl®/Pamorelin® in Europe, Latin America and Pamorelin® in India. The 6-month-formulation has been registered and is available in Europe and the US in prostate cancer.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments.
Debiopharm International is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.
For more information about Debiopharm Group™, please visit:

Debiopharm International SA Contact    
Christelle Tur
Communication Coordinator
Tel.: +41(0)21-321-01-11

Additional Media Contacts
In London
Brian Hudspith
Tel: +44(0)20-7379-5151

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel: +1-212-845-4292

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
2. Go To Market Consulting Inc. and Debiopharm Group Collaborate to Identify Early Stage In-licensing Opportunities on the US West Coast
3. Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics
4. Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers
5. Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients
6. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
7. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
8. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
9. Practice Fusion Partners with Healthagens Practice iQ to Help Physician Groups Perform as ACOs
10. Chris Kilbee Appointed Group Director of UBM Pharma Portfolio
11. FDA Warns of Health Complications from Transvaginal Mesh Erosion, Says Life Care Solutions Group
Post Your Comments:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
Breaking Medicine News(10 mins):